Which is the best MRI marker of malignancy for atypical cirrhotic nodules: Hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration

Journal of Magnetic Resonance Imaging

Volumn 36, Issue 3, 2012, Pages 648-657

  Golfieri, Rita ^a   Grazioli, Luigi ^b   Orlando, Emanuela ^b   Dormi, Ada ^a   Lucidi, Vincenzo ^a   Corcioni, Beniamino ^a   Dettori, Ernesto ^b   Romanini, Laura ^b   Renzulli, Matteo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Radiology Unit   (Italy)

Author keywords

atypical liver nodules; cirrhosis; Gd EOB DTPA enhanced magnetic resonance imaging; hepatobiliary phase hypointensity; T2 weight hyperintensity

Indexed keywords

GADOXETIC ACID;

ADULT; AGED; ARTICLE; CANCER GRADING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; LIGHT INTENSITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER NODULE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BIOLOGICAL MARKERS; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER CIRRHOSIS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84865313463     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.23685     Document Type: Article

References (40)

1. Mion F, Grozel L, Boillot O, Paliard P, Berger F,. Adult cirrhotic liver explants: precancerous lesions and undetected small hepatocellular carcinomas. Gastroenterology 1996; 111: 1587-1592. (Pubitemid 26404223)
2. International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49: 658-664.
3. Kojiro M,. Focus on dysplastic nodules and early hepatocellular carcinoma: an Eastern point of view. Liver Transpl 2004; 10: S3-S8. (Pubitemid 38240092)
4. Kojiro M, Roskams T,. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 2005; 25: 133-142. (Pubitemid 40781066)
5. Kojiro M,. Diagnostic discrepancy of early hepatocellular carcinoma between Japan and West. Hepatol Res 2007; 37 (Suppl 2): S121-S124.
6. Kudo M,. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology 2008; 75 (Suppl 1): 1-12.
7. Kudo M,. Multistep human hepatocarcinogenesis: correlation of imaging with pathology. J Gastroenterol 2009; 44 (Suppl 19): 112-118.
8. Bruix J, Sherman M,. Management of hepatocellular carcinoma: an update. AASLD practice guideline. Hepatology 2011; 53: 1020-1022.
9. Leoni S, Piscaglia F, Golfieri R, et al. The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol 2010; 105: 599-609.
10. Golfieri R, Renzulli M, Lucidi V, Corcioni B, Trevisani F, Bolondi L,. Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (> 2 cm) HCC in cirrhosis. Eur Radiol 2011; 21: 1233-1242.
11. Kelekis NL, Semelka RC, Worawattanakul S, et al. Hepatocellular carcinoma in North America: a multiinstitutional study of appearance on T1-weighted, T2-weighted, and serial gadolinium-enhanced gradient-echo images. AJR Am J Roentgenol 1998; 170: 1005-1013. (Pubitemid 28172890)
12. Kim YK, Kwak HS, Han YM, Kim CS,. Usefulness of combining sequentially acquired gadobenate dimeglumine-enhanced magnetic resonance imaging and resovist-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: comparison with computed tomography hepatic arteriography and computed tomography arterioportography using 16-slice multidetector computed tomography. J Comput Assist Tomogr 2007; 31: 702-711. (Pubitemid 47482489)
13. Choi SH, Lee JM, Yu NC, et al. Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI. AJR Am J Roentgenol 2008; 191: 529-536.
14. Willatt JM, Hussain HK, Adusumilli S, Marrero JA,. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008; 247: 311-330.
15. Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY,. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 2010; 255: 459-466.
16. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology 1996; 199: 177-183. (Pubitemid 26098637)
17. Vogl TJ, Kummel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996; 200: 59-67. (Pubitemid 26197732)
18. Saito K, Kotake F, Ito N, et al. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci 2005; 4: 1-9.
19. Kim JI, Lee JM, Choi JY, et al. The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol 2008; 43: 202-210. (Pubitemid 351643147)
20. Kogita S, Imai Y, Okada M, et al. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol 2010; 20: 2405-2413.
21. Hecht EM, Holland AE, Israel GM, et al. Hepatocellular carcinoma in the cirrhotic liver: gadolinium-enhanced 3D T1-weighted MR imaging as a stand-alone sequence for diagnosis. Radiology 2006; 239: 438-447.
22. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA 2000; 284: 3043-3045.
23. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 1995; 22: 983-993.
24. Grazioli L, Morana G, Caudana R, et al. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings. Invest Radiol 2000; 35: 25-34. (Pubitemid 30033604)
25. Haradome H, Grazioli L, Tsunoo M, et al. Can MR fluoroscopic triggering technique and slow rate injection provide appropriate arterial phase images with reducing artifacts on gadoxetic acid-DTPA (Gd-EOB-DTPA)-enhanced hepatic MR imaging? J Magn Reson Imaging 2010; 32: 334-340.
26. Rode A, Bancel B, Douek P, et al. Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J Comput Assist Tomogr 2001; 25: 327-336. (Pubitemid 32440782)
27. Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006; 101: 513-523. (Pubitemid 43340927)
28. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008; 47: 97-104. (Pubitemid 351171046)
29. Bolondi L, Gaiani S, Celli N, et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 2005; 42: 27-34. (Pubitemid 40911308)
30. Tsuboyama T, Onishi H, Kim T, et al. Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging-correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 2010; 255: 824-833.
31. Motosugi U, Ichikawa T, Sou H, et al. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology 2010; 256: 151-158.
32. Grazioli L, Morana G, Caudana R, et al. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings. Invest Radiol 2000; 35: 25-34. (Pubitemid 30033604)
33. Gabata T, Matsui O, Kadoya M, et al. Delayed MR imaging of the liver: correlation of delayed enhancement of hepatic tumors and pathologic appearance. Abdom Imaging 1998; 23: 309-313. (Pubitemid 28213309)
34. Manfredi R, Maresca G, Baron RL, et al. Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA). J Magn Reson Imaging 1999; 9: 704-710. (Pubitemid 29211165)
35. Narita M, Hatano E, Arizono S, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009; 44: 793-798.
36. Xu PJ, Yan FH, Wang JH, Shan Y, Ji Y, Chen CZ,. Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver. J Comput Assist Topmogr 2010; 34: 506-512.
37. Pasquinelli F, Belli G, Mazzoni LN, Grazioli L, Colagrande S,. Magnetic resonance diffusion-weighted imaging: quantitative evaluation of age-related changes in healthy liver parenchyma. Magn Reson Imaging 2011; 29: 805-812.
38. Padhani AR, Liu G, Mu-Koh D, et al. Diffusion weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009; 11: 102-125.
39. Ransohoff DF, Feinstein AR,. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med 1978; 299: 926-930. (Pubitemid 9050459)
40. Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med 2003; 138: W1-W12.